An Opportunity to Harmonise the Approach to Patients' Care Pathways for Rare and Complex Diseases: RarERN Path™.

As a matter of fact, organisation always matters when discussing about healthcare, since it is fundamental in order to ensure the delivery of the most appropriate care to patients in the most appropriate way. Unfortunately, the pandemic brought by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) imposed a huge reorganisation of the healthcare systems, with several repercussions on the care of several chronic conditions, that were in many cases discontinued. This was the case of rare diseases (RDs), conditions that even under normal circumstances can experience diagnostic delays and difficulties in receiving appropriate care.

Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency.

Real world data (RWD) refers to healthcare information that is routinely collected in electronic healthcare records (EHR), hospital and pharmacy records, patient and disease registries, and health insurance databases. The collection and analysis of this vast amount of data is an important complement to that obtained from conventional randomised controlled trials (RCT). Real world data has been used for healthcare quality improvements, to conduct clinical trials, to support drug and device development, and to inform medical guidelines.

An EU approach to health system performance assessment: Building trust and learning from each other.

EU countries have recently joined forces to carry out common work on health systems performance assessment (HSPA). After the signature of the Tallinn Charter in 2008, a small group of countries brought the issue of HSPA on the EU agenda; this led the European commission and member states to set up an expert group on HSPA in 2014. This group started by facilitating the exchange of best practices and lessons learnt, with an eye to avoiding duplications with activities of international organisations.

Silver paper: the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease--a report of the European Summit on Age-Related Disease.

BACKGROUND. In September 2008, under the French Presidency of the European Union and with the support of the Polish Minister of Health, a European Summit on Age-Related Disease was organised inWroclaw (Poland). At this meeting, European politicians, gerontologists and geriatricians gathered to discuss a common approach to future challenges related to age-related disease.

European silver paper on the future of health promotion and preventive actions, basic research and clinical aspects of age-related disease.

The current article is a statement of the meeting with international and multidisciplinary participation, held in Wrocław, Poland on September 11-13, 2008. The meeting was devoted to working out a position focusing on the challenge for individuals, health care systems, biological, psychosocial, epidemiological, medical, and public health sciences in the ageing populations of the twenty-first century. The statement is presented as an overview, in tabular format, of the current European situation regarding basic biological research on ageing, health promotion and preventive action, clinical care for older people, and recommendations for future actions.

Metal-nucleic acid cages.

Metal-nucleic acid cages are a promising new class of materials. Like metallo-supramolecular cages, these systems can use their metals for redox, photochemical, magnetic and catalytic control over encapsulated cargo. However, using DNA provides the potential to program pore size, geometry, chemistry and addressability, and the ability to symmetrically and asymmetrically position transition metals within the three-dimensional framework.

[Menopausal changes in circadian heart rate variability].

Objectives: Presence of cardiovascular symptoms in perimenopausal period is suggested to be associated with the decrease of cardiac autonomic nervous system (cANS) regulatory function.

Aim: Aim of the study was to evaluate whether menopause affects circadian heart rate variability (HRV).

Method: 42 healthy women were divided into two equal groups: premenopausal (age 43 +/- 7 years) and postmenopausal (age 53 +/- 3 years, 3.

Rearrangement of molybdocene tetraoxotetrasulfide Cp2MoS4O4 to Give [(Cp2MoS2H)2](HSO4)2: a novel proton-stabilized molybdocene disulfide dimer.

Cp(2)MoS(4), 1, in CH(2)Cl(2) undergoes extensive oxidation by m-CPBA at -78 degrees C to give a 1,1,4,4-tetroxide, 2 (59%). Tetraoxide 2 rearranges at room temperature to give an unusual sulfur-atom protonated molybdocene disulfide dimer [(Cp(2)MoS(2)H)(2)](HSO(4))(2), 3. Crystal data for 3 are P, a = 6.

Insertion of SO(2) into the S-S bond of Cp(2)MoS(2) and Cp(2)MoS(2)O to give molybdocene dithiosulfate and bis(O-alkylthiosulfates).

Cp(2)MoS(2), 3, reacts with SO(2) in CH(2)Cl(2)/EtOH mixtures to give Cp(2)MoS(3)O(2), 4, wherein the SO(2) has inserted into the S-S bond to give a dithiosulfate ligand. Crystal data for 4: P2(1)/n, a = 7.6782(6) A, b = 14.